Dafna Gladman

787 total citations · 1 hit paper
10 papers, 582 citations indexed

About

Dafna Gladman is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, Dafna Gladman has authored 10 papers receiving a total of 582 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Rheumatology, 6 papers in Immunology and 4 papers in Hematology. Recurrent topics in Dafna Gladman's work include Spondyloarthritis Studies and Treatments (7 papers), Psoriasis: Treatment and Pathogenesis (6 papers) and Rheumatoid Arthritis Research and Therapies (5 papers). Dafna Gladman is often cited by papers focused on Spondyloarthritis Studies and Treatments (7 papers), Psoriasis: Treatment and Pathogenesis (6 papers) and Rheumatoid Arthritis Research and Therapies (5 papers). Dafna Gladman collaborates with scholars based in Canada, United States and Japan. Dafna Gladman's co-authors include Philip J. Mease, Christopher T. Ritchlin, Chin H. Lee, Désirée van der Heijde, Daniel Braun, Raquel Cuchacovich, Catherine L Shuler, Chen‐Yen Lin, Masato Okada and Mark Lebwohl and has published in prestigious journals such as Annals of the Rheumatic Diseases, Journal of the American Academy of Dermatology and Arthritis Research & Therapy.

In The Last Decade

Dafna Gladman

5 papers receiving 570 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1

2016 431 citations Philip J. Mease, Désirée van der Heijde et al. Annals of the Rheumatic Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dafna Gladman Canada	4	455	394	221	118	63	10	582
Elinor Mody United States	10	357 0.8×	395 1.0×	199 0.9×	74 0.6×	20 0.3×	15	529
Jason Coarse United States	12	514 1.1×	418 1.1×	231 1.0×	90 0.8×	25 0.4×	47	691
Sabrina Rebello United States	14	206 0.5×	403 1.0×	166 0.8×	24 0.2×	40 0.6×	48	467
S. Mudivarthy Canada	3	489 1.1×	578 1.5×	363 1.6×	61 0.5×	27 0.4×	4	705
J Medich United States	3	333 0.7×	394 1.0×	233 1.1×	55 0.5×	16 0.3×	4	475
Benjamin Porter-Brown United Kingdom	7	160 0.4×	264 0.7×	142 0.6×	10 0.1×	32 0.5×	10	394
Esen Kasapoğlu Günal Türkiye	10	136 0.3×	336 0.9×	99 0.4×	14 0.1×	17 0.3×	23	492
B. Kroegler Italy	10	179 0.4×	216 0.5×	82 0.4×	13 0.1×	39 0.6×	24	383
Nashla Barroso United States	4	109 0.2×	107 0.3×	48 0.2×	23 0.2×	61 1.0×	7	324
Sau Mei Tse China	10	125 0.3×	314 0.8×	57 0.3×	12 0.1×	39 0.6×	18	372

Countries citing papers authored by Dafna Gladman

Since Specialization

Citations

This map shows the geographic impact of Dafna Gladman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dafna Gladman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dafna Gladman more than expected).

Fields of papers citing papers by Dafna Gladman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dafna Gladman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dafna Gladman. The network helps show where Dafna Gladman may publish in the future.

Co-authorship network of co-authors of Dafna Gladman

This figure shows the co-authorship network connecting the top 25 collaborators of Dafna Gladman. A scholar is included among the top collaborators of Dafna Gladman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dafna Gladman. Dafna Gladman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Gladman, Dafna, Philip J. Mease, Laure Gossec, et al.. (2025). Effect of Bimekizumab on Patient-Reported Outcomes and Work Productivity in Patients With Psoriatic Arthritis: 1-Year Results From 2 Phase III Studies. The Journal of Rheumatology. 52(5). 466–478.

Kharouf, Fadi, et al.. (2025). The association between cigarette smoking and radiographic progression in Psoriatic Arthritis. Seminars in Arthritis and Rheumatism. 71. 152653–152653.

Gladman, Dafna, et al.. (2025). Identifying characteristics for a cost-effective psoriatic arthritis biomarker test: a development-focused health technology assessment. International Journal of Technology Assessment in Health Care. 41(1). e29–e29.

Bonilla, Dennisse, et al.. (2025). TYPE I INTERFERON STATUS AND CLINICAL MANIFESTATIONS IN A LARGE COHORT OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. The Journal of Rheumatology. 52(Suppl 1). 99.1–99.

Gladman, Dafna, et al.. (2024). Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis. Arthritis Research & Therapy. 26(1). 218–218.

Kharouf, Fadi & Dafna Gladman. (2024). Treatment controversies in spondyloarthritis and psoriatic arthritis: focus on biologics and targeted therapies. Expert Review of Clinical Immunology. 20(11). 1381–1400. 1 indexed citations

Mease, Philip J., Désirée van der Heijde, Christopher T. Ritchlin, et al.. (2016). Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Annals of the Rheumatic Diseases. 76(1). 79–87. 431 indexed citations breakdown →

Mease, Philip J., Masato Okada, Mitsumasa Kishimoto, et al.. (2016). OP0109 Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52 Week Results from A Phase 3 Study (Spirit-P1). Annals of the Rheumatic Diseases. 75. 96–96. 3 indexed citations

Lebwohl, Mark, Jerry Bagel, Joel M. Gelfand, et al.. (2007). From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis. Journal of the American Academy of Dermatology. 58(1). 94–105. 84 indexed citations

10.

Gladman, Dafna, et al.. (1993). DILEMMAS IN NEUROPSYCHIATRIC LUPUS. Rheumatic Disease Clinics of North America. 19(4). 795–814. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact